Title |
Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer
|
---|---|
Published in |
Breast Cancer Research and Treatment, October 2011
|
DOI | 10.1007/s10549-011-1799-1 |
Pubmed ID | |
Authors |
Yunwei Han, Zhihao Yu, Shaoyan Wen, Bin Zhang, Xuchen Cao, Xin Wang |
Abstract |
Neutropenia is one of the most important dose-limiting toxicities and often the reason for dose reduction. In this study we aimed to assess whether chemotherapy-induced neutropenia could be a marker of efficacy and associate with increased survival. Data from a retrospective survey for early breast cancer patients in our hospital were reviewed. Three hundred and thirty-five patients who had been treated with six cycles of cyclophosphamide, epirubicin, and fluorouracil (CEF) were studied. The association between chemotherapy-induced neutropenia and overall survival (OS) was assessed. According to a multivariate Cox model with time-varying covariates, hazard ratios of death were 0.434 (95% confidence interval (CI), 0.298-0.634; P < 0.001) for patients with mild neutropenia, and 0.640 (95% CI, 0.42-0.975; P = 0.038) for those with severe neutropenia. Neutropenia occurring in early breast cancer patients is an independent predictor of increased survival. These findings suggest that neutropenia in patients who receive chemotherapy is strongly associated with a better prognosis. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Switzerland | 1 | 3% |
Unknown | 39 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 7 | 18% |
Other | 5 | 13% |
Researcher | 4 | 10% |
Student > Master | 4 | 10% |
Professor | 2 | 5% |
Other | 9 | 23% |
Unknown | 9 | 23% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 11 | 28% |
Biochemistry, Genetics and Molecular Biology | 5 | 13% |
Immunology and Microbiology | 4 | 10% |
Agricultural and Biological Sciences | 3 | 8% |
Nursing and Health Professions | 3 | 8% |
Other | 4 | 10% |
Unknown | 10 | 25% |